Clinical Trials
83 trialsNCT07491445 2026-05-14
RASolute 303
Revolution Medicines, Inc.
Phase 3 Recruiting
NCT06119217 2026-05-13
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Trishula Therapeutics, Inc.
Phase 2 Completed
NCT07578337 2026-05-13
NUMANTIA-2
Nelum Corp
Phase 2 Not yet recruiting
NCT06608927 2026-05-08
PRISM-1
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT04104672 2026-05-07
ARC-8
Arcus Biosciences, Inc.
Phase 1 Active not recruiting
NCT07563738 2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2 Recruiting
NCT06390059 2026-04-30
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
NovoCure Ltd.
Phase 2 Completed
NCT07076121 2026-04-30
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07255404 2026-04-29
A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
BioNTech SE
Phase 2 Recruiting
NCT06625320 2026-04-27
RASolute 302
Revolution Medicines, Inc.
Phase 3 Active not recruiting
NCT07020221 2026-04-22
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Phase 1/2 Recruiting
NCT07223047 2026-04-13
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
NCT06445062 2026-04-01
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT06360354 2026-03-31
MTAPESTRY 103
Amgen
Phase 1 Recruiting
NCT05586516 2026-03-30
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
iOnctura
Phase 1/2 Completed
NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT04894643 2026-03-20
PARC
EBG MedAustron GmbH
Phase NA Recruiting
NCT03816163 2026-03-12
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT02705196 2026-02-24
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
Phase 1/2 Completed
NCT06059001 2026-01-14
OMO-103-02
Peptomyc S.L.
Phase 1 Active not recruiting
NCT06361888 2025-12-30
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Hutchmed
Phase 2/3 Recruiting
NCT04390399 2025-12-15
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03417921 2025-10-01
Pancreatic
Ability Pharmaceuticals SL
Phase 1/2 Suspended
NCT07079228 2025-09-23
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05669482 2025-09-02
RAMP205
Verastem, Inc.
Phase 1/2 Active not recruiting
NCT04306900 2025-07-29
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT06592664 2025-06-06
FORTIFIDE
Lisata Therapeutics, Inc.
Phase 1/2 Withdrawn
NCT02340117 2025-05-30
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
SynerGene Therapeutics, Inc.
Phase 2 Active not recruiting
NCT02047500 2025-05-11
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
ImmunoGenesis
Phase 1 Terminated
NCT01834235 2025-05-07
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Precision Biologics, Inc
Phase 1/2 Terminated
NCT05919537 2025-04-18
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
Hummingbird Bioscience
Phase 1 Active not recruiting
NCT06532331 2025-04-18
A Phaseâ… Study of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
Ono Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT03563144 2025-02-21
QUILT-3.088: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT06538207 2025-02-06
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Ono Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02672917 2025-01-28
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
BioNTech SE
Phase 1 Terminated
NCT05859750 2024-12-16
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Akeso
Phase 2 Recruiting
NCT03329248 2024-12-12
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03252808 2024-12-09
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.
Takara Bio Inc.
Phase 1 Active not recruiting
NCT05254171 2024-11-06
ASPIRE
Panbela Therapeutics, Inc.
Phase 2/3 Recruiting
NCT06662669 2024-10-29
YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1/2 Not yet recruiting
NCT04683939 2024-10-02
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
BioNTech SE
Phase 1/2 Terminated
NCT03517176 2024-08-28
CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
Lisata Therapeutics, Inc.
Phase 1 Completed
NCT03586869 2024-08-27
QUILT-3.080: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03136406 2024-06-11
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387098 2024-05-22
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT02231723 2023-11-18
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT04329949 2023-11-18
RELIANT
Corcept Therapeutics
Phase 3 Terminated
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed